US EditionPublished • loading... • Updated
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
Summary by The Health Standard
39 Articles
39 Articles
Farm Talk Newspaper+38 Reposted by 38 other sources
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
NEW ORLEANS, Nov. 9, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved potent, durable reductions in ApoC3 and…
·Parsons, United States
Read Full ArticleCoverage Details
Total News Sources39
Leaning Left3Leaning Right1Center16Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
15%
C 80%
Factuality
To view factuality data please Upgrade to Premium
